BACKGROUND: The epidemiology of painful episodes in infants and younger children with SCD has not been well studied, particularly for pain managed at home. PROCEDURE: SCD infants identified by newborn screening were enrolled in a longitudinal observational study of pain symptoms requiring parents to report the presence or absence of pain daily. When sickle cell related-pain events occurred, pain occurrence, location, associated symptoms and the treatment provided also were reported. RESULTS: 103 children were enrolled at a median age of 7.2 months; 50 had an SS genotype, 32 SC, 6 SB(0)thalassemia, and 15 SB(+)thalassemia. Parents/guardians reported for a median of 3.8 years (range 0.3-7.6 years) assessing pain for a total of 141,197 days, excluding any period of recurrent transfusions, with an additional 28,079 days of missing data (16%). Children had pain reported on 2,288 days (1.6%), representing 768 distinct episodes of pain, of which 108 required hospitalizations (14%). Pain locations and symptoms consistent with dactylitis were most prevalent (80%) in the 0-12 month age group, and became progressively less prevalent thereafter. Group-based trajectory modeling of pain episode or pain day frequency identified several trajectory groups with progressively older ages of peak pain frequency, which included 40-45% of SS/SB(0)thalassemia and 10-12% of SC/SB(+)thalassemia children. CONCLUSIONS: Pain is relatively infrequent in SCD infants and young children and commonly managed at home. Analyses of longitudinal pain trajectories suggest several different pain trajectories, differing in their frequency, age of onset, and age at peak pain frequency with clinical implications for hydroxyurea management.
BACKGROUND: The epidemiology of painful episodes in infants and younger children with SCD has not been well studied, particularly for pain managed at home. PROCEDURE: SCDinfants identified by newborn screening were enrolled in a longitudinal observational study of pain symptoms requiring parents to report the presence or absence of pain daily. When sickle cell related-pain events occurred, pain occurrence, location, associated symptoms and the treatment provided also were reported. RESULTS: 103 children were enrolled at a median age of 7.2 months; 50 had an SS genotype, 32 SC, 6 SB(0)thalassemia, and 15 SB(+)thalassemia. Parents/guardians reported for a median of 3.8 years (range 0.3-7.6 years) assessing pain for a total of 141,197 days, excluding any period of recurrent transfusions, with an additional 28,079 days of missing data (16%). Children had pain reported on 2,288 days (1.6%), representing 768 distinct episodes of pain, of which 108 required hospitalizations (14%). Pain locations and symptoms consistent with dactylitis were most prevalent (80%) in the 0-12 month age group, and became progressively less prevalent thereafter. Group-based trajectory modeling of pain episode or pain day frequency identified several trajectory groups with progressively older ages of peak pain frequency, which included 40-45% of SS/SB(0)thalassemia and 10-12% of SC/SB(+)thalassemiachildren. CONCLUSIONS:Pain is relatively infrequent in SCDinfants and young children and commonly managed at home. Analyses of longitudinal pain trajectories suggest several different pain trajectories, differing in their frequency, age of onset, and age at peak pain frequency with clinical implications for hydroxyurea management.
Authors: Samir K Ballas; Robert L Bauserman; William F McCarthy; Oswaldo L Castro; Wally R Smith; Myron A Waclawiw Journal: Am J Hematol Date: 2010-08 Impact factor: 10.047
Authors: S T Miller; L A Sleeper; C H Pegelow; L E Enos; W C Wang; S J Weiner; D L Wethers; J Smith; T R Kinney Journal: N Engl J Med Date: 2000-01-13 Impact factor: 91.245
Authors: Winfred C Wang; Russell E Ware; Scott T Miller; Rathi V Iyer; James F Casella; Caterina P Minniti; Sohail Rana; Courtney D Thornburg; Zora R Rogers; Ram V Kalpatthi; Julio C Barredo; R Clark Brown; Sharada A Sarnaik; Thomas H Howard; Lynn W Wynn; Abdullah Kutlar; F Daniel Armstrong; Beatrice A Files; Jonathan C Goldsmith; Myron A Waclawiw; Xiangke Huang; Bruce W Thompson Journal: Lancet Date: 2011-05-14 Impact factor: 79.321
Authors: Wally R Smith; Samir K Ballas; William F McCarthy; Robert L Bauserman; Paul S Swerdlow; Martin H Steinberg; Myron A Waclawiw Journal: Pain Med Date: 2011-04-11 Impact factor: 3.750
Authors: Jeroen W B Peters; Renata Schouw; K J S Anand; Monique van Dijk; Hugo J Duivenvoorden; Dick Tibboel Journal: Pain Date: 2005-04 Impact factor: 6.961
Authors: Courtney D Thornburg; Beatrice A Files; Zhaoyu Luo; Scott T Miller; Ram Kalpatthi; Rathi Iyer; Phillip Seaman; Jeffrey Lebensburger; Ofelia Alvarez; Bruce Thompson; Russell E Ware; Winfred C Wang Journal: Blood Date: 2012-08-22 Impact factor: 22.113
Authors: F M Gill; L A Sleeper; S J Weiner; A K Brown; R Bellevue; R Grover; C H Pegelow; E Vichinsky Journal: Blood Date: 1995-07-15 Impact factor: 22.113
Authors: Deepika S Darbari; Johnson P Hampson; Eric Ichesco; Nadja Kadom; Gilbert Vezina; Iordanis Evangelou; Daniel J Clauw; James G Taylor Vi; Richard E Harris Journal: J Pain Date: 2015-08-18 Impact factor: 5.820
Authors: Sarah L Reeves; Hannah K Jary; Jennifer P Gondhi; Jean L Raphael; Lynda D Lisabeth; Kevin J Dombkowski Journal: Clin Pediatr (Phila) Date: 2019-05-21 Impact factor: 1.168
Authors: Jinny A Paul; Anupam Aich; Juan E Abrahante; Ying Wang; Rebecca S LaRue; Susan K Rathe; Krystina Kalland; Aditya Mittal; Ritu Jha; Fei Peng; David A Largaespada; Anindya Bagchi; Kalpna Gupta Journal: Sci Data Date: 2017-05-16 Impact factor: 6.444